ALB and chronic kidney disease: Eligible patients were adults with stage 3 or 4 CKD and albumin to creatinine ratio (ACR) ≥265 mg/g or eGFR decline rate ≥3.0 mL/min/1.73 m2 in the preceding 12 months.